Published in Physiol Rev on July 01, 2015
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol (2016) 1.66
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. Diabetes Care (2016) 1.04
Neural circuitry and immunity. Immunol Res (2015) 0.97
Attenuation of high sucrose diet-induced insulin resistance in tryptophan 2,3-dioxygenase deficient Drosophila melanogaster vermilion mutants. Integr Obes Diabetes (2015) 0.81
Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World J Gastroenterol (2016) 0.81
Metformin use and young age lung cancer: A case series report. Oncol Lett (2016) 0.80
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. J Clin Oncol (2016) 0.79
Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis. Oncotarget (2016) 0.78
Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis. J Mol Biomark Diagn (2015) 0.78
2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget (2017) 0.77
General and Abdominal Adiposity and Risk of Death in HBV Versus Non-HBV Carriers: A 10-Year Population-based Cohort Study. Medicine (Baltimore) (2016) 0.77
BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer. Cell Mol Life Sci (2016) 0.77
Role of PTEN in Oxidative Stress and DNA Damage in the Liver of Whole-Body Pten Haplodeficient Mice. PLoS One (2016) 0.76
Preserving Healthy Muscle during Weight Loss. Adv Nutr (2017) 0.75
Host-Microbiome Interaction and Cancer: Potential Application in Precision Medicine. Front Physiol (2016) 0.75
Attenuation of high sucrose diet-induced insulin resistance in ABC transporter deficient white mutant of Drosophila melanogaster. Integr Obes Diabetes (2016) 0.75
Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise. Curr Breast Cancer Rep (2016) 0.75
Body mass index and the risk of cancer incidence in patients with type 2 diabetes in Japan: Results from the National Center Diabetes Database. J Diabetes Investig (2016) 0.75
Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone. Medicine (Baltimore) (2016) 0.75
Proliferation and metastatic potential of endometrial cancer cells in response to metformin treatment in a high versus normal glucose environment. Oncol Lett (2016) 0.75
Psychological Aspects of Bariatric Surgery as a Treatment for Obesity. Curr Obes Rep (2017) 0.75
Diabetic complications within the context of aging: Nicotinamide adenine dinucleotide redox, insulin C-peptide, sirtuin 1-liver kinase B1-adenosine monophosphate-activated protein kinase positive feedback and forkhead box O3. J Diabetes Investig (2016) 0.75
The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway. Oncol Lett (2017) 0.75
Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study. Oncotarget (2017) 0.75
Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene (2017) 0.75
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Cancer-related inflammation. Nature (2008) 34.21
Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 25.43
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med (1999) 16.57
The hormone resistin links obesity to diabetes. Nature (2001) 15.49
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Adipokines in inflammation and metabolic disease. Nat Rev Immunol (2011) 8.92
Statin use and reduced cancer-related mortality. N Engl J Med (2012) 8.51
THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol (1927) 7.64
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia (2009) 7.06
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem (2000) 6.86
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer (2007) 5.57
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest (2010) 5.39
Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst (2005) 5.32
Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol (2013) 5.28
LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science (2009) 5.23
Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA (2008) 4.48
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol (2005) 4.37
MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res (2009) 4.32
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med (2011) 3.84
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ (2012) 3.82
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia (2012) 3.70
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 3.53
27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science (2013) 3.52
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia (2011) 3.52
Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab (2011) 3.38
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev (2007) 3.16
Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol (2009) 3.14
A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 3.13
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology (2012) 2.74
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res (1998) 2.67
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet (1997) 2.67
Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia (2007) 2.54
Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation (2008) 2.48
Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab (2008) 2.47
Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol (1995) 2.36
Diabetic dyslipidemia. Endocrinol Metab Clin North Am (2006) 2.35
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst (2011) 2.27
Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes (2003) 2.22
Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2011) 2.19
Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis (2008) 2.19
Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev (2001) 2.18
Central obesity and breast cancer risk: a systematic review. Obes Rev (2003) 2.16
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care (2011) 2.16
Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia (2011) 2.15
Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 2.13
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res (2002) 2.11
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A (2012) 2.11
Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care (2003) 2.02
The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol (2008) 2.00
Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci (2004) 1.97
Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol (2012) 1.97
Metformin in cancer: translational challenges. J Mol Endocrinol (2012) 1.94
Carcinoma of the pancreas. I. A clinical and pathologic study of 609 necropsied cases. II. The relation of carcinoma of the pancreas to diabetes mellitus. Am J Pathol (1957) 1.93
Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia (2011) 1.89
Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst (2012) 1.86
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J (1990) 1.82
Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract (2012) 1.79
Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst (2003) 1.79
Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol (2013) 1.78
High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat (2008) 1.78
Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol (2010) 1.66
Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res (2013) 1.65
Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) (2009) 1.64
A phenotype-sensitizing Apoe-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse. Genetics (2002) 1.61
Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol (1999) 1.60
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat (2003) 1.60
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia (2012) 1.55
Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol (1999) 1.53
Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer (2005) 1.52
Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.49
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. Am J Epidemiol (2008) 1.48
Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat (2012) 1.47
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab (2006) 1.44
Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc (2011) 1.43
Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care (2012) 1.42
Insulin treatment for the early 80s: facts and questions about old and new insulins and their usage. Diabetes Care (1981) 1.42
Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev (1995) 1.41
Role of cholesterol in the development and progression of breast cancer. Am J Pathol (2010) 1.38
The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev (2005) 1.37
Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res (2013) 1.37
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem (2012) 1.36
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J (2002) 1.33
Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A (2014) 1.33
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care (2008) 1.33
Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer (2004) 1.33
An epidemiological investigation of cancer of the endometrium. Cancer (1966) 1.32